Treatment of malignant pleural mesothelioma with combination of carboplatin, caelyx, and gemzitabine: the CCG study of the Nordic mesothelioma group

G. Hillerdal, J. B. Sorensen, S. Sundstrom, H. Riska, A. Vikstrom (Stockholm, Linkoping, Sweden; Copenhagen, Denmark; Trondheim, Norway; Helsinki, Finland)

Source: Annual Congress 2004 - Mesothelioma and malignant pleural effusions - pollution and cancer
Session: Mesothelioma and malignant pleural effusions - pollution and cancer
Session type: Thematic Poster Session
Number: 3274
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Hillerdal, J. B. Sorensen, S. Sundstrom, H. Riska, A. Vikstrom (Stockholm, Linkoping, Sweden; Copenhagen, Denmark; Trondheim, Norway; Helsinki, Finland). Treatment of malignant pleural mesothelioma with combination of carboplatin, caelyx, and gemzitabine: the CCG study of the Nordic mesothelioma group. Eur Respir J 2004; 24: Suppl. 48, 3274

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Systemic treatment of malignant mesothelioma
Source: Eur Respir Mon; 2009: 44: 419–434
Year: 2009

Polychemotherapy experience in pleural mesothelioma with or without pemetrexed
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009


Second-line chemotherapy in malignant pleural mesothelioma (MPM)
Source: Eur Respir J 2002; 20: Suppl. 38, 273s
Year: 2002

Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020

Chemotherapy for treatment of malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells
Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Year: 2018

Multimodal therapy in malignant pleural mesothelioma (MPM)
Source: Eur Respir J 2002; 20: Suppl. 38, 187s
Year: 2002

Comparison between treatment with IL2, and IL2 in combination with chemotherapy in malignant pleural mesothelioma
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009


Pleurectomy/decortication for malignant pleural mesothelioma: a single-centre experience.
Source: Virtual Congress 2020 – Thoracic surgery: developments in diagnostics and outcomes
Year: 2020


Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
Source: Eur Respir J 2010; 36: 1362-1369
Year: 2010



Malignant pleural mesothelioma: new treatment modalities
Source: Annual Congress 2005 - Clinical year in review
Year: 2005

Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method
Source: Eur Respir J 2002; 20: Suppl. 38, 272s
Year: 2002

Belgian prospective, multicenter, observational study of patients with malignant pleural mesothelioma treated with pemetrexed plus platinum
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014



Pleurodesis for malignant pleural effusions: A comparison of bleomycin or tranexamic acid alone versus a combination of both
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013

A phase II study with gemcitabine (GEM) plus irinotecan (CPT11) in malignant mesothelioma (MM): preliminary report
Source: Eur Respir J 2002; 20: Suppl. 38, 186s
Year: 2002

Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010

Malignant mesothelioma and chemotherapy: efficacy and influence on survival of patients
Source: Eur Respir J 2002; 20: Suppl. 38, 272s
Year: 2002

Local (LICT) and systemic immunochemotherapy (SICT) after surgery in malignant pleural mesothelioma (MPM)
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004